Cognition Therapeutics presents analyses at AD/PD 2024

Cognition Therapeutics is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD 2024 Alzheimer’s & Parkinson’s Diseases Conference. Two posters summarize proteomic analyses from the Phase 2 SEQUEL study which measured the impact of CT1812 on synapse function as determined by changes in brain wave patterns recorded by quantitative electroencephalogram. These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition’s lead candidate. Among the proteins identified, those that were strongly correlated with CT1812 treatment effects were associated with protein trafficking, autophagy, neuroinflammation and microglial response. The third poster summarizes proteomic analyses from the Phase 1 SPARC study, which was designed to measure the impact of CT1812 on synaptic density. Pathways identified in these proteomic analyses support a role for CT1812 in modulating Abeta biology and neuroinflammation, among other disease-relevant processes.